Nivolumab,Ipilimumab,Cabozantinib,Sunitinib
BMS,Pfizer
['sunitinib', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'cabo ', 'nivo']
important 44month followup update of chrckmate 9er presented by . overall, benefit over sunitinib is maintained. some open questions are about durability of therapy (will there be a tail) and how best to treat favorable risk (no clear os benefit) #gu23 
Oncologist, physician-scientist, Assistant Professor @YaleCancer @YaleMed | cancer immunotherapy, genomics, kidney cancer | tweets ≠ medical advice.